Xenetic Biosciences, Inc. (XBIO) Stock: A Strong Pick In The Biotechnology Space?

0

Xenetic Biosciences, Inc. (XBIO) is headed down in the market in today’s trading session. The stock, one that is focused on the biotechnology space, is currently trading at $1.08 after tumbling -6.90% so far today. In terms of biotechnology companies, there are quite a few factors that have the ability to lead to declines in the market. News is one of the most common reasons for movement. Here are the most recent stories relating to XBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-08-19 08:30AM Xenetic Biosciences, Inc. Provides Business Outlook
Jul-22-19 08:00AM Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
Jul-17-19 08:45AM Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
Jul-05-19 01:19PM Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering
Jun-24-19 09:08AM Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Nonetheless, when making a decision with regard to investing, investors should take a look at much more than news, this is especially the case in the speculative biotech industry. Here’s what’s happening in regard to Xenetic Biosciences, Inc..

How XBIO Has Been Trending

Although a single session decline, like the move that we’re seeing from Xenetic Biosciences, Inc. may make some investors fearful, a single session move alone should not be the reason for a decision to, or not to, invest in a company. It’s generally smart to take a look at trends for a period longer than a single trading day. As it relates to XBIO, below are the movements that investors have experienced:

  • Past 5 Sessions – In the past week, XBIO has seen a change in value that amounts to 6.42%.
  • Monthly – The monthly ROI from Xenetic Biosciences, Inc. has been -25.64%.
  • Quarterly – Throughout the past three months, the stock has produced a return of -89.46%
  • Past Six Months – Throughout the previous 6 months, investors have seen a change that amounts to -94.00% from the stock.
  • Year To Date – Since the open of this year XBIO has generated a ROI of -94.11%.
  • Annually – Lastly, in the last year, investors have seen a change of -96.02% from XBIO. Throughout this period, the stock has traded at a high of -97.57% and a low price of 8.76%.

Key Ratios

Digging into a few key ratios having to do with a stock can provide investors a look of just how dangerous and/or rewarding a stock pick might be. Below are some of the most important ratios to look at when looking at XBIO.

Short Ratio – The short ratio is a measure of short interest. As the ratio goes higher, it shows that more investors have a belief that the value of the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we also see a lot of short squeezes in the sector. Nonetheless, in relation to Xenetic Biosciences, Inc., it’s short ratio comes to 0.61.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure the company’s abilities to pay its debts when they come due with only quick assets or current assets. Because many biotech many companies rely on continued support from investors, these ratios can seem bad. Nonetheless, several better companies in the biotechnology industry come with strong current and quick ratios. As far as XBIO, the quick and current ratios add up to 1.00 and 1.00 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price of the stock. In this case, the book to share value ratio comes in at 11.78.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is an important ratio to consider. In terms of XBIO, the cash to share value ratio works out to 0.27.

What Analysts Think About Xenetic Biosciences, Inc.

While it’s rarely a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to consider their opinions to validate your own opinions before making investment decisions in the biotechnology industry. Here are the recent moves that we have seen from analysts as it relates to XBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Are Big Money Players Doing With Xenetic Biosciences, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in XBIO, here’s what we’re seeing:

  • Institutions – As it stands now, institutions own 30.30% of XBIO. On the other hand, it is worth mentioning that institutional ownership has seen a move in the amount of 0 over the last quarter.
  • Insider Holdings – as it relates to insiders, insiders of the company currently hold 7.50% of the company. Insider ownership of the company has seen a change of 0 over the past quarter.

What’s Going On With Share Counts?

Investors tend to have an interest in the counts of shares both available and outstanding. In terms of Xenetic Biosciences, Inc., currently there are 3.74M with a float of 2.77M. These numbers mean that out of the total of 3.74M shares of XBIO currently in existence today, 2.77M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to XBIO, the short percent of the float is 8.93%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, XBIO has generated revenue in the amount of $0 with earnings coming in at 19.40%. On a quarter over quarter basis, earnings have seen movement of 43.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social trends and other publicly available data, but I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at data? If so, write a comment below and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here